The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Doxtinex will be available in March 1997. In a clinical trial involving approximately 450 patients, Dostinex was compared with bromocriptine in treating hyperporlactinemia. Side Effects Clinical studies also showed the safety profile of Dostinex compares favorably to bromocriptine. Two percent of 221 patients taking Dostinex discontinues treatment due to side effects during the eight-weed study, versus six percent of 231 patients taking bromocriptine.
Nausea is the most common side effect of both drugs.
Dostinex is contraindicated in patients with uncontrolled hypertension or known hypersensitivity to ergot derivatives. Additional Information Hyperprolactinemia is usually caused by a benign tumor on the pituitary gland that results in excess production of prolactin, the hormone that controls lactation. Doctors treat from 70,000 to 100,000 patients with the condition each year, the vast majority of whom are women. It most commonly affects women ages 20-50 and can cause cessation of menstruation, excessive milk discharge and infertility. In men the condition can cause decreased libido and impotence.